The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|March 26, 2020
Parenteral Drug Association (PDA)
PDA is the leading global provider of science, technology, regulatory information, and education for the bio/pharmaceutical community.
PDA is the leading global provider of science, technology, regulatory information, and education for the bio/pharmaceutical community. For nearly 75 years, PDA has developed sound, practical technical information and resources to advance science and regulation through the expertise of our more than 10,500 members worldwide. We promote dialogue on new technology and regulations to ensure high-quality pharmaceutical production.
Parenteral Drug Association (PDA)
4350 East West Hwy, Suite 600 Bethesda, MD 20814
info@pda.org
tel. 301.656.5900
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.